TriArm Therapeutics

Cell therapy company that has designed a novel way to develop and continuously evolve immune cell (CAR-T) therapeutics clinically and has developed a fast 2-day procedure that can produce autologous CAR-T products at a fraction of the cost of today’s products. The company was incubated by Panacea and Venture Partner Jay Zhang serves as CEO. TriArm’s proprietary transposase efficiently carries message DNA into the genome of an immune cell, converting it into a uniquely potent cancer fighting agent. The combined approach not only results in vastly increased yield to satisfy therapeutic dosage, but also generates more immune naïve, potent, and persistent T cells.